Back to Explorer
Research PaperResearchia:202603.30031[Data Science > Statistics]

Targeted learning of heterogeneous treatment effect curves for right censored or left truncated time-to-event data

Matthew Pryce

Abstract

In recent years, there has been growing interest in causal machine learning estimators for quantifying subject-specific effects of a binary treatment on time-to-event outcomes. Estimation approaches have been proposed which attenuate the inherent regularisation bias in machine learning predictions, with each of these estimators addressing measured confounding, right censoring, and in some cases, left truncation. However, the existing approaches are found to exhibit suboptimal finite-sample performance, with none of the existing estimators fully leveraging the temporal structure of the data, yielding non-smooth treatment effects over time. We address these limitations by introducing surv-iTMLE, a targeted learning procedure for estimating the difference in the conditional survival probabilities under two treatments. Unlike existing estimators, surv-iTMLE accommodates both left truncation and right censoring while enforcing smoothness and boundedness of the estimated treatment effect curve over time. Through extensive simulation studies under both right censoring and left truncation scenarios, we demonstrate that surv-iTMLE outperforms existing methods in terms of bias and smoothness of time-varying effect estimates in finite samples. We then illustrate surv-iTMLE's practical utility by exploring heterogeneity in the effects of immunotherapy on survival among non-small cell lung cancer (NSCLC) patients, revealing clinically meaningful temporal patterns that existing estimators may obscure.


Source: arXiv:2603.26502v1 - http://arxiv.org/abs/2603.26502v1 PDF: https://arxiv.org/pdf/2603.26502v1 Original Link: http://arxiv.org/abs/2603.26502v1

Submission:3/30/2026
Comments:0 comments
Subjects:Statistics; Data Science
Original Source:
View Original PDF
arXiv: This paper is hosted on arXiv, an open-access repository
Was this helpful?

Discussion (0)

Please sign in to join the discussion.

No comments yet. Be the first to share your thoughts!